Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2020 | The potential of biomarkers in dementia

Giancarlo Logroscino, MD, PhD, Università degli Studi di Bari, Bari, Italy, discusses how biomarkers will be key in the future to determine the subtypes of dementia and their therapeutic approaches. Biomarkers will be important to identify and anticipate disease pathology for optimal therapeutic results. They will also be needed to distinguish between the different subtypes of dementia, such as Alzheimer’s disease, vascular, frontotemporal, and Lewy body dementia. Additionally, this will determine the route of therapeutic approach and disease management. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.


Giancarlo Logroscino is associate editor of the Journal Neuroepidemiology, Karger and PI or co-PI of several grants, mainly from national agencies.